GU-01: Glycyrrhizin in Prostate Cancer - Trial NCT06378346
Access comprehensive clinical trial information for NCT06378346 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Illinois at Chicago and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Illinois at Chicago
Timeline & Enrollment
Phase 2
May 01, 2024
Mar 01, 2026
Primary Outcome
Number of participants that have a change in prostate-specific antigen (PSA) before GLY administration,Number of participants that have a change in prostate-specific antigen (PSA) after GLY administration and prior to radical prostatectomy
Summary
This is a pilot, randomized, window-of-opportunity treatment trial in which participants with
 previously untreated prostate cancer (PCa) who are candidates for surgery (radical
 prostatectomy)
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06378346
Non-Device Trial